Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin?KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827
A news report from Xinhua: With the opening of the International Horticultural Exhibition 2024 Chengdu, a series of short videos integrating Chengdu's beautiful scenery with ancient poetry has stirred discussions on social media platforms. Netizens...
OKX, a leading Web3 technology company, today announced that its hosting an exclusive X Spaces event focused on Proof of Reserves. The event aims to amplify trust and transparency in the crypto industry and will feature OKX leadership and renowned...
The report titled "5G Enterprise Market by Equipment (Distributed Antenna System, Radio Node, Service Node), Organization Size (Large Enterprises, SMEs), End User - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents...
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have...
Ecogensus, a pioneering resource technology company, today announced its expansion into innovative materials derived from mixed wastes, unlocking the potential value of billions of tons of unused resources. These versatile new materials are...
